This Special Issue explores new drug and behavioural trends during the Covid-19 Pandemic. We welcome multidisciplinary contributions aimed at enhancing the understanding of how “physical distancing” and other radical changes in our...
Las personas encargadas del tratamiento por abuso de sustancias, quienes ejercen la medicina clínica, los/las extensionistas, las clínicas de salud pública, entre otros, deben conocer la información que se detalla a continuación. La...
2021 INCSR–Volume I: Drug and Chemical Control (As submitted to Congress)
To read the full report, please visit: https://www.state.gov/2021-incsr-volume-i-drug-and-chemical-control-as-submitted-to-congress/
Abstract
Importance: Patient-reported outcomes in the treatment of opioid dependence may differ between subcutaneously administered depot buprenorphine and daily sublingual buprenorphine.
Objective: To compare patient satisfaction between...
Addiction neuroscience models posit that recurrent drug use increases reactivity to drug-related cues and blunts responsiveness to natural rewards, propelling a cycle of hedonic dysregulation that drives addictive behavior. Here...
High comorbidity exists between mental illness and substance use disorders (SUD). Patients in psychiatry living with problematic alcohol or drug consumption can experience a sense of exclusion, where seeking help for...
Over the past two decades, the National Drug Abuse Treatment Clinical Trials Network (CTN), a program of the National Institute on Drug Abuse (NIDA), has expanded from the initial six Nodes to 16 Nodes, as a nationwide consortium...
Recent studies suggest that the endocannabinoid system could play an important role in the physiopathology of obsessive-compulsive disorder (OCD). There are reports of effective treatment with derivatives of tetrahydrocannabinol (THC). The...
